Most major stock indexes across the globe moved upwards on a weekly basis, taking support from the uptick in US equities.

Despite this success, recent market challenges and a decline in the company ... Despite the leadership change at Novo Nordisk causing the stock price to stumble, a 10.4% increase in the company ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

Markets don't seem to have fully digested Moody's downgrade of the U.S. credit rating, Mitsubishi UFJ Morgan Stanley ...

Stock was still down by Monday morning (19 May). Novo Nordisk did not provide a timeline for revealing its new CEO, saying only that the search for a successor is ongoing. Jørgensen will continue ...

Monday, BMO Capital Markets maintained its "Market Perform" rating and a $64.00 price target for Novo Nordisk (NYSE: NVO) stock, a pharmaceutical giant with a market capitalization of $290.78 billion.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...